Physician profile
Christopher Michael Wolfe
NPI 1417073503
$2,593.51
in general payments reported to CMS, 2019-2025
15 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.06 · 2020: $200 · 2021: $447 · 2022: $207 · 2023: $424 · 2024: $513 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $840.29 | 2023-2025 | Puraply, Novachor, Cygnus Dual |
| Abbvie INC. | $513.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $333.40 | 2022-2025 | |
| Ucb, INC. | $240.97 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $170.66 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $129.58 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $103.72 | 2020-2025 | |
| Leo Pharma INC. | $76.25 | 2021-2025 | Anzupgo, Adbry |
| Janssen Biotech, INC. | $44.45 | 2020-2025 | Stelara, Tremfya, Simponi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.78 | 2024-2025 | Spevigo |
| Biofrontera INC. | $27.94 | 2020 | |
| Lilly USA, LLC | $23.03 | 2024 | Ebglyss |
| Allergan, INC. | $21.79 | 2021 | |
| Amgen INC. | $16.58 | 2020 | |
| Kerecis Limited | $11.96 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.